ClinicalTrials.gg
RecruitingNCT07409181Updated Nov 12, 2026

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

A Phase 2 interventional study of BI 3000202 and Placebo in Systemic Lupus Erythematosus, sponsored by Boehringer Ingelheim. Recruiting at 139 sites in 21 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 12, 2026Site recruiting status changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Planned enrollment
51st of 407
405 · median 70
Started
2026
with 28 others
Phase 2
120 of 477
10 open now
Primary completion
2029-02
later than 95 of 125 live
Registered
466th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 51st largest by planned enrollment of the 407 interventional ones that give a count, is one of 29 that started in 2026, is one of 120 in phase 2, reaches primary completion later than 95 of the 125 other live ones, and was the 466th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

81 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition.

Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE.

Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Lupus
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adult patients from ≥18 years (or alternative age for adults based on local regulations) to \<75 years
  2. Confirmed Systemic Lupus Erythematosus (SLE) diagnosis meeting the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria at least 24 weeks prior to screening
  3. At least one of the following positive at screening: Antinuclear Antibodies (ANA) ≥1:80 or anti-double-stranded Deoxyribonucleic Acid (dsDNA) antibody or anti-Smith antibody

    - Total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥6 points and clinical SLEDAI-2K score ≥4 points

  4. At least 1 British Isles Lupus Assessment Group (BILAG) A and/or 1 BILAG B grade at screening, with sufficient disease activity according to both investigator and adjudicator
  5. On SLE background therapy with a maximum of 1 and/or 1 antimalarial for ≥8 weeks and at a stable dose for ≥4 weeks before screening and/or oral at a dose of ≤30 mg/day prednisone or equivalent, stable for ≥2 weeks before screening (Visit 1) Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Drug-induced SLE
  2. Scleroderma (except linear scleroderma that does not interfere with assessments of SLE disease activity) or in the opinion of the investigator or adjudicator elements of other connective tissue disease that would interfere with interpretation of test results or SLE clinical assessments
  3. Active or unstable lupus neuropsychiatric manifestations, including but not limited to any condition as defined by BILAG A criteria in the neuropsychiatric system, with the exception of mononeuritis/mononeuropathy multiplex, chorea, and polyneuropathy
  4. Lupus nephritis that may require a change in immune-modulating treatment or which demonstrates serum creatinine that is unstable or >2 × (ULN) and/or Urine Protein Creatinine Ratio (UPCR) that is unstable or > 3mg/mg (339 mg/mmol)
  5. Oral (prednisone or equivalent) >30 mg/day at screening Further exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
405 participants (estimated)

Study arms

  • Experimental
    Arm 1: BI 3000202 dose 1

    Drug: BI 3000202

  • Experimental
    Arm 2: BI 3000202 dose 2

    Drug: BI 3000202

  • Experimental
    Arm 3: BI 3000202 dose 3

    Drug: BI 3000202

  • Experimental
    Arm 4: BI 3000202 dose 4

    Drug: BI 3000202

  • Placebo comparator
    Arm 5: Placebo

    Drug: Placebo

Interventions

  • BI 3000202 at different doses

  • DrugPlacebo

    Placebo matching BI 3000202

06

What researchers measure

Primary outcomes

  1. Achievement of a Systemic Lupus Erythematosus Responder Index (SRI)-4 response

    Time frame: At Week 32

Secondary outcomes

  1. Achievement of SRI-4 response

    Time frame: At Week 52

  2. Achievement of SRI-4 response and oral corticosteroid reduction to ≤5 mg/day prednisone or equivalent

    Time frame: At Week 32

  3. Achievement of Lupus Low Disease Activity State (LLDAS)

    Time frame: At Week 32

07

Study locations

94 of 139 sites recruiting

Showing the first 100 of 139 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Feb 2029, 33 months after the start.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 33 months is close to that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 13, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Feb 4, 2029
CompletionEst.
Jul 8, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 5 sites removed. 17 sites changed recruiting status (17 now recruiting)
Show 17 sites
  • Cross Creek Medical Clinic, PA · Fayetteville, United StatesNot yet recruiting→Recruiting
  • Military medical academy - MHAT Pleven · Pleven, BulgariaNot yet recruiting→Recruiting
  • Delta Health Care · Bucharest, RomaniaNot yet recruiting→Recruiting
  • University of California Los Angeles · Torrance, United StatesNot yet recruiting→Recruiting
  • Hospitalar Moinhos de Vento · Porto Alegre, BrazilNot yet recruiting→Recruiting
  • Inovace Pesquisa Clínica · Salvador, BrazilNot yet recruiting→Recruiting
  • Poliklinika Bonifarm Zagreb · Zagreb, CroatiaNot yet recruiting→Recruiting
  • Centrul Clinic De Boli Reumatismale Dr. Ion Stoia · Bucharest, RomaniaNot yet recruiting→Recruiting
  • Belfast City Hospital · Belfast, United KingdomNot yet recruiting→Recruiting
  • Addenbrooke's Hospital · Cambridge, United KingdomNot yet recruiting→Recruiting
  • Oklahoma Medical Research Foundation · Oklahoma City, United StatesNot yet recruiting→Recruiting
  • Medical Complex Sveti Ivan Rilski EOOD · Plovdiv, BulgariaNot yet recruiting→Recruiting
  • Xiangya Hospital, Central South University · Changsha, ChinaNot yet recruiting→Recruiting
  • Clinica de la Costa Ltda. · Barranquilla, ColombiaNot yet recruiting→Recruiting
  • CIREEM SAS (Centro de Investigacion en Reumatologia y Especialidades Medicas) · Bogotá, ColombiaNot yet recruiting→Recruiting
  • Solmed Polyclinic · Zagreb, CroatiaNot yet recruiting→Recruiting
  • Institutul Clinic Fundeni · Bucharest, RomaniaNot yet recruiting→Recruiting
Show 4 added (3 Brazil, 1 South Africa)
  • SAPIENS - Instituto de Estudos e Pesquisa Clinica · Curitiba, Brazil
  • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto · São José do Rio Preto, Brazil
  • Cape Town - Arthritis Clinical Research Trial Unit · Cape Town, South Africa
  • A2Z Clinical Centro Avançado de Pesquisa Clinica · Valinhos, Brazil
Show 5 removed
  • SAPIENS - Instituto de Estudos e Pesquisa Clínica · Curitiba, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto · São José do Rio Preto, Brazil
  • Azidus Centro de Pesquisa Clinica Avancada · Valinhos, Brazil
  • Rheumazentrum Prof. Dr. med. Gunther Neeck · Bad Doberan, Germany
  • Guy's Hospital · London, United Kingdom
across 4 updates, Oct 1, 2026 – Nov 12, 2026
Show all 4 updates
  1. Nov 12, 2026
    7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • Oklahoma Medical Research Foundation · Oklahoma City, United StatesNot yet recruiting→Recruiting
    • Medical Complex Sveti Ivan Rilski EOOD · Plovdiv, BulgariaNot yet recruiting→Recruiting
    • Xiangya Hospital, Central South University · Changsha, ChinaNot yet recruiting→Recruiting
    • Clinica de la Costa Ltda. · Barranquilla, ColombiaNot yet recruiting→Recruiting
    • CIREEM SAS (Centro de Investigacion en Reumatologia y Especialidades Medicas) · Bogotá, ColombiaNot yet recruiting→Recruiting
    • Solmed Polyclinic · Zagreb, CroatiaNot yet recruiting→Recruiting
    • Institutul Clinic Fundeni · Bucharest, RomaniaNot yet recruiting→Recruiting
    + 1 other change: verification date
  2. Oct 28, 2026
    1 site removed. 7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • University of California Los Angeles · Torrance, United StatesNot yet recruiting→Recruiting
    • Hospitalar Moinhos de Vento · Porto Alegre, BrazilNot yet recruiting→Recruiting
    • Inovace Pesquisa Clínica · Salvador, BrazilNot yet recruiting→Recruiting
    • Poliklinika Bonifarm Zagreb · Zagreb, CroatiaNot yet recruiting→Recruiting
    • Centrul Clinic De Boli Reumatismale Dr. Ion Stoia · Bucharest, RomaniaNot yet recruiting→Recruiting
    • Belfast City Hospital · Belfast, United KingdomNot yet recruiting→Recruiting
    • Addenbrooke's Hospital · Cambridge, United KingdomNot yet recruiting→Recruiting
    Show 1 removed
    • Guy's Hospital · London, United Kingdom
    + 1 other change: identifiers
  3. Oct 14, 2026
    1 site added, 2 sites removed. Delta Health Care is now Recruiting
    Show site
    • A2Z Clinical Centro Avançado de Pesquisa Clinica · Valinhos, Brazil
    Show 2 removed
    • Azidus Centro de Pesquisa Clinica Avancada · Valinhos, Brazil
    • Rheumazentrum Prof. Dr. med. Gunther Neeck · Bad Doberan, Germany
    + 1 other change: verification date
  4. Oct 1, 2026
    3 sites added, 2 sites removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Cross Creek Medical Clinic, PA · Fayetteville, United StatesNot yet recruiting→Recruiting
    • Military medical academy - MHAT Pleven · Pleven, BulgariaNot yet recruiting→Recruiting
    Show 3 added (2 Brazil, 1 South Africa)
    • SAPIENS - Instituto de Estudos e Pesquisa Clinica · Curitiba, Brazil
    • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto · São José do Rio Preto, Brazil
    • Cape Town - Arthritis Clinical Research Trial Unit · Cape Town, South Africa
    Show 2 removed
    • SAPIENS - Instituto de Estudos e Pesquisa Clínica · Curitiba, Brazil
    • Fundação Faculdade Regional de Medicina de São José do Rio Preto · São José do Rio Preto, Brazil

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07409181
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Apr 20, 2026
Primary completion
Feb 4, 2029 (estimated)
Completion
Jul 8, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 3000202

Start the discussion